Rachna T. Shroff, MD, MS, FASCO

Rachna Shroff, MD, MS, FASCO, is interim clinical affairs director, associate director of Clinical Investigations, and co-lead of Gastrointestinal Clinical Research Team at The University of Arizona Cancer Center. She is also a professor in the Department of Medicine, chief of the Division of Hematology/Oncology, medical director of the Oncology Service Line, and associate dean of Clinical and Translational Research at The University of Arizona College of Medicine.

Articles by Rachna T. Shroff, MD, MS, FASCO

TOPAZ-1: Chemotherapy + Durvalumab in Biliary Tract Cancers

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University

March 15th 2023

Centering discussion on the TOPAZ-1 trial of chemotherapy in combination with durvalumab, panelists consider how this regimen has impacted clinical practice.

Standard of Care Systemic Therapies for Biliary Tract Cancers

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University

March 8th 2023

Key opinion leaders in the field of biliary tract cancers highlight mainstay systemic therapy regimens within the treatment paradigm.

Role for Liver Transplant in Biliary Tract Cancers

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University

March 8th 2023

A brief discussion on the continued role of liver transplant in biliary tract cancers and when it is appropriate to consider a patient for this procedure.

Liver-Directed Treatment Strategies in Biliary Tract Cancers

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University

March 1st 2023

A comprehensive review of liver-directed therapies available to aid in the management of biliary tract cancers.

Biliary Tract Cancers: Surgical and Perioperative Treatment Strategies

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University

March 1st 2023

Moving on to identify specific treatment modalities, panelists discuss the surgical and perioperative strategies used to manage biliary tract cancers.

Advent of Molecular Testing in Biliary Tract Cancers

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University

February 22nd 2023

Key opinion leaders review the advent of molecular testing in biliary tract cancers and consider its impact on informing treatment decisionmaking.

Optimizing the Staging of Biliary Tract Cancers

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University

February 22nd 2023

Focused conversation on the optimal workup and staging of biliary tract cancers within the current paradigm.

Clinical Scenario: Diagnostic Strategies to Identify Biliary Tract Cancers

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University

February 15th 2023

Centering focus on a patient scenario, panelists break down mainstay diagnostic strategies used to identify biliary tract cancers.

Overview on Biliary Tract Cancers and Their Rising Incidence

ByMilind Javle, MD, The University of Texas MD Anderson Cancer Center,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Rachna T. Shroff, MD, MS, FASCO,Flavio G. Rocha, MD, FACS, FSSO, Oregon Health & Science University

February 15th 2023

Expert panelists open their discussion on biliary tract cancers by identifying various subsets and noting the growing incidence of these diseases.

Dr. Shroff on Results of the SWOG 1815 Trial in Advanced Biliary Tract Cancers

ByRachna T. Shroff, MD, MS, FASCO

January 20th 2023

Rachna T. Shroff, MD, MS, discusses efficacy data from the phase 3 SWOG 1815 trial investigating nab-paclitaxel plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in newly diagnosed patients with advanced biliary tract cancers.

Dr. Shroff on the Utility of the HIMALAYA Regimen in HCC

ByRachna T. Shroff, MD, MS, FASCO

November 7th 2022

Rachna T. Shroff, MD, MS, discusses the utility of combining anti–CTLA-4 and anti–PD-1 therapies in hepatocellular carcinoma.

Dr. Shroff on Remaining Unmet Needs for Patients With HCC

ByRachna T. Shroff, MD, MS, FASCO

October 11th 2022

Rachna T. Shroff, MD, MS, discusses remaining unmet needs for patients with hepatocellular carcinoma.

A New Frontier in Cholangiocarcinoma Management and Treatment

ByRachna T. Shroff, MD, MS, FASCO

November 18th 2021

This content was developed in collaboration with Servier Pharmaceuticals and Onc Live

Rachna T. Shroff, MD, MS, FASCO

Articles by Rachna T. Shroff, MD, MS, FASCO

TOPAZ-1: Chemotherapy + Durvalumab in Biliary Tract Cancers

Standard of Care Systemic Therapies for Biliary Tract Cancers

Role for Liver Transplant in Biliary Tract Cancers

Liver-Directed Treatment Strategies in Biliary Tract Cancers

Biliary Tract Cancers: Surgical and Perioperative Treatment Strategies

Advent of Molecular Testing in Biliary Tract Cancers

Optimizing the Staging of Biliary Tract Cancers

Clinical Scenario: Diagnostic Strategies to Identify Biliary Tract Cancers

Overview on Biliary Tract Cancers and Their Rising Incidence

Dr. Shroff on Results of the SWOG 1815 Trial in Advanced Biliary Tract Cancers

Dr. Shroff on the Utility of the HIMALAYA Regimen in HCC

Dr. Shroff on Remaining Unmet Needs for Patients With HCC

A New Frontier in Cholangiocarcinoma Management and Treatment

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC

Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM

NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer

Dana-Farber Study Finds Dual Immunotherapy May Help Certain Patients With Advanced NSCLC Live Longer